Sirolimus Experience in Blue Rubber Bleb Nevus Syndrome.

ington, DC 20036. 10. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101:3868–3871. 11. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Oncol Res Treat. 2004;27:269–272. 12. Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148:768–776. 13. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700–708. 14. Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood. 2012; 120:978–984. 15. Kaspers GJ, Zimmermann M, Fleischhack G, et al. Relapsed acute myeloid leukemia in children and adolescents: interim report of the international randomised phase III study relapsed AML 2001/01. Blood. 2006;108:2013. 16. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2006;21:66–71. 17. Chevallier P, Roland V, Mahé B, et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Res. 2005;29: 1003–1007. 18. Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2008; 26:2390–2395. 19. Sibson K, Steward C, Moppett J, et al. Dismal long‐term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now? Br J Haematol. 2009;146:342–344. 20. Reinhardt D, Zwaan CM, Sander A, et al. Gemtuzumab ozogamicin in refractory childhood acute myeloid leukemia. Blood. 2010;116:1075. 21. Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res. 2005;11:7164s–7170s. 22. Capria S, Trisolini SM, Minotti C, et al. Ara-C, idarubicine and gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients. Mediterr J Hematol Infect Dis. 2012;4:e2012072. 23. Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26:5192–5197. 24. Filanovsky K, Shvidel L, Shtalrid M. Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia. J Clin Oncol. 2010;28: e115–e116. 25. Prebet T, Etienne A, Devillier R, et al. Improved outcome of patients with low‐ and intermediate‐risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. Cancer. 2011;117:974–981.